{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:46:23Z","timestamp":1784299583773,"version":"3.55.0"},"reference-count":46,"publisher":"Walter de Gruyter GmbH","issue":"6","funder":[{"name":"Grant of Palacky University","award":["IGA_LF_2024_004"],"award-info":[{"award-number":["IGA_LF_2024_004"]}]},{"name":"Conceptual development of research organization supported by the Ministry of Health, Czech Republic","award":["FNOL, 00098892"],"award-info":[{"award-number":["FNOL, 00098892"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Malignant effusions, pleural effusion or ascites, represent a common problem in cancer patients. Pleural effusion in a cancer patient may be caused also by non-neoplastic conditions, and the diagnosis of malignant pleural effusion is established by the demonstration of tumor cells in\u00a0pleural fluid. Microscopical detection of tumor cells in pleural fluid often fails, and there is an unmet medical need for more sensitive methods. New approaches, including isolation using magnetic beads coated with monoclonal antibodies targeting antigens expressed on tumor cells not only increase the diagnostic sensitivity, but also provide material for the analysis of predictive biomarkers. The advent of new technologies illustrates the incremental role of laboratory medicine in the management of patients with malignant effusions.<\/jats:p>","DOI":"10.1515\/cclm-2025-0197","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:34:38Z","timestamp":1740767678000},"page":"1069-1074","source":"Crossref","is-referenced-by-count":3,"title":["Pleural effusion as a sample matrix for laboratory analyses in cancer management: a perspective"],"prefix":"10.1515","volume":"63","author":[{"given":"Martina","family":"Spisarov\u00e1","sequence":"first","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry , Palack\u00fd University and University Hospital , Olomouc , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"\u0160tudentov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry , Palack\u00fd University and University Hospital , Olomouc , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate\u0159ina","family":"Hol\u00e1","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry , Palack\u00fd University and University Hospital , Olomouc , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry , Palack\u00fd University and University Hospital , Olomouc , Czech Republic"},{"name":"Department of Oncology and Radiotherapy , Charles University Medical School and Teaching Hospital , Hradec Kr\u00e1lov\u00e9 , Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"2025042506015785114_j_cclm-2025-0197_ref_001","doi-asserted-by":"crossref","unstructured":"Porcel, JM, Light, RW. Pleural fluid analysis: are light\u2019s criteria still relevant after half a century? Clin Chest Med 2021;42:599\u2013609. https:\/\/doi.org\/10.1016\/j.ccm.2021.07.003.","DOI":"10.1016\/j.ccm.2021.07.003"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_002","doi-asserted-by":"crossref","unstructured":"Ferreiro, L, S\u00e1nchez-S\u00e1nchez, R, Vald\u00e9s, L, Kummerfeldt, CE, Huggins, JT. Concordant and discordant exudates and their effect on the accuracy of light\u2019s criteria to diagnose exudative pleural effusions. Am J Med Sci 2016;352:549\u201356. https:\/\/doi.org\/10.1016\/j.amjms.2016.08.016.","DOI":"10.1016\/j.amjms.2016.08.016"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_003","doi-asserted-by":"crossref","unstructured":"Jany, B, Welte, T. Pleural effusion in adults-etiology, diagnosis, and treatment. Dtsch Arztebl Int 2019;116:377\u201386. https:\/\/doi.org\/10.3238\/arztebl.2019.0377.","DOI":"10.3238\/arztebl.2019.0377"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_004","doi-asserted-by":"crossref","unstructured":"Light, RW. Clinical practice. Pleural effusion. N Engl J Med 2002;346:1971\u20137. https:\/\/doi.org\/10.1056\/nejmcp010731.","DOI":"10.1056\/NEJMcp010731"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_005","doi-asserted-by":"crossref","unstructured":"Light, RW, Macgregor, MI, Luchsinger, PC, Ball, WCJr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507\u201313. https:\/\/doi.org\/10.7326\/0003-4819-77-4-507.","DOI":"10.7326\/0003-4819-77-4-507"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_006","doi-asserted-by":"crossref","unstructured":"Munavvar, M, Bodtger, U, Carus, A, Cordovilla, R, Naik, S, Salud, A, et al.. Current trends in treating malignant pleural effusion: evidence, guidelines, and best practice recommendations. JCO Oncol Pract 2025:1\u20138. in press.","DOI":"10.1200\/OP.24.00387"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_007","doi-asserted-by":"crossref","unstructured":"Aboudara, M, Maldonado, F. Update in the management of pleural effusions. Med Clin 2019;103:475\u201385. https:\/\/doi.org\/10.1016\/j.mcna.2018.12.007.","DOI":"10.1016\/j.mcna.2018.12.007"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_008","doi-asserted-by":"crossref","unstructured":"Rodr\u00eeguez-Panadero, F, Borderas Naranjo, F, L\u00f3pez Mej\u00eeas, J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989;2:366\u20139. https:\/\/doi.org\/10.1183\/09031936.93.02040366.","DOI":"10.1183\/09031936.93.02040366"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_009","doi-asserted-by":"crossref","unstructured":"Roberts, ME, Neville, E, Berrisford, RG, Antunes, G, Ali, NJ. Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax 2010;65:ii32\u201340. https:\/\/doi.org\/10.1136\/thx.2010.136994.","DOI":"10.1136\/thx.2010.136994"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_010","doi-asserted-by":"crossref","unstructured":"Psallidas, I, Kalomenidis, I, Porcel, JM, Robinson, BW, Stathopoulos, GT. Malignant pleural effusion: from bench to bedside. Eur Respir Rev 2016;25:189\u201398. https:\/\/doi.org\/10.1183\/16000617.0019-2016.","DOI":"10.1183\/16000617.0019-2016"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_011","unstructured":"Kumar, AK, Mantri, SN. Lymphangitic carcinomatosis. StatPearls. Treasure Island, FL: StatPearls Publishing; 2023."},{"key":"2025042506015785114_j_cclm-2025-0197_ref_012","doi-asserted-by":"crossref","unstructured":"Klimek, M. Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970\u20132018. Postgrad Med J 2019;131:309\u201318. https:\/\/doi.org\/10.1080\/00325481.2019.1595982.","DOI":"10.1080\/00325481.2019.1595982"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_013","doi-asserted-by":"crossref","unstructured":"Scherpereel, A, Astoul, P, Baas, P, Berghmans, T, Clayson, H, de Vuyst, P, et al.. Guidelines of the European respiratory society and the European society of thoracic surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479\u201395. https:\/\/doi.org\/10.1183\/09031936.00063109.","DOI":"10.1183\/09031936.00063109"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_014","doi-asserted-by":"crossref","unstructured":"Gonnelli, F, Hassan, W, Bonifazi, M, Pinelli, V, Bedawi, EO, Porcel, JM, et al.. Malignant pleural effusion: current understanding and therapeutic approach. Respir Res 2024;25:47. https:\/\/doi.org\/10.1186\/s12931-024-02684-7.","DOI":"10.1186\/s12931-024-02684-7"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_015","doi-asserted-by":"crossref","unstructured":"Porcel, JM, Gasol, A, Bielsa, S, Civit, C, Light, RW, Salud, A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;20:654\u20139. https:\/\/doi.org\/10.1111\/resp.12496.","DOI":"10.1111\/resp.12496"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_016","doi-asserted-by":"crossref","unstructured":"Yang, Y, Du, J, Wang, YS, Kang, HY, Zhai, K, Shi, HZ. Prognostic impact of pleural effusion in patients with malignancy: a systematic review and meta-analysis. Clin Transl Sci 2022;15:1340\u201354. https:\/\/doi.org\/10.1111\/cts.13260.","DOI":"10.1111\/cts.13260"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_017","doi-asserted-by":"crossref","unstructured":"Wang, TF, Chu, SC, Lee, JJ, Yang, GG, Huang, WH, Chang, ET, et al.. Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment. Asia Pac J Clin Oncol 2017;13:304\u201313. https:\/\/doi.org\/10.1111\/ajco.12658.","DOI":"10.1111\/ajco.12658"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_018","doi-asserted-by":"crossref","unstructured":"Pardessus Otero, A, Rafecas-Codern, A, Porcel, JM, Serra-Mitj\u00e0, P, Ferreiro, L, Botana-Rial, M, et al.. Malignant pleural effusion: a multidisciplinary approach. Open Respir Arch 2024;6:100349. https:\/\/doi.org\/10.1016\/j.opresp.2024.100349.","DOI":"10.1016\/j.opresp.2024.100349"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_019","doi-asserted-by":"crossref","unstructured":"Orlandi, R, Cara, A, Cassina, EM, Degiovanni, S, Libretti, L, Pirondini, E, et al.. Malignant pleural effusion: diagnosis and treatment-up-to-date perspective. Curr Oncol 2024;31:6867\u201378. https:\/\/doi.org\/10.3390\/curroncol31110507.","DOI":"10.3390\/curroncol31110507"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_020","doi-asserted-by":"crossref","unstructured":"Wang, MC, Wang, CL, Chen, TL, Chang, JW, Lu, JJ, Chang, PY, et al.. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clin Chem Lab Med 2017;55:1979\u201386. https:\/\/doi.org\/10.1515\/cclm-2016-0809.","DOI":"10.1515\/cclm-2016-0809"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_021","doi-asserted-by":"crossref","unstructured":"Zhao, W, Jiang, TW, Zheng, WQ, Hu, ZD. Diagnostic accuracy of adenosine deaminase for tuberculous pleural effusion: age does matter. Clin Chem Lab Med 2024;62:e116\u201318. https:\/\/doi.org\/10.1515\/cclm-2023-0916.","DOI":"10.1515\/cclm-2023-0916"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_022","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Barrios, C, S\u00e1nchez-Herrero, E, Garcia-Sim\u00f3n, N, Barqu\u00edn, M, Clemente, MB, Provencio, M, et al.. ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma. Clin Chem Lab Med 2021;59:1221\u20139. https:\/\/doi.org\/10.1515\/cclm-2020-1465.","DOI":"10.1515\/cclm-2020-1465"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_023","doi-asserted-by":"crossref","unstructured":"Shin, S, Kim, J, Kim, Y, Cho, SM, Lee, KA. Assessment of real-time PCR method for detection of EGFR mutation using both supernatant and cell pellet of malignant pleural effusion samples from non-small-cell lung cancer patients. Clin Chem Lab Med 2017;55:1962\u20139. https:\/\/doi.org\/10.1515\/cclm-2016-0851.","DOI":"10.1515\/cclm-2016-0851"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_024","doi-asserted-by":"crossref","unstructured":"Son, SM, Woo, CG, Han, HS, Lee, KH, Lim, YH, Lee, OJ. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma. Clin Chem Lab Med 2020;58:1547\u201355. https:\/\/doi.org\/10.1515\/cclm-2019-1139.","DOI":"10.1515\/cclm-2019-1139"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_025","doi-asserted-by":"crossref","unstructured":"Zhang, L, Zhou, Y, Yang, S, Zhu, Q, Xu, J, Mu, Y, et al.. Tumor specific protein 70 targeted tumor cell isolation technology can improve the accuracy of cytopathological examination. Clin Chem Lab Med 2025;63:1208\u201315. https:\/\/doi.org\/10.1515\/cclm-2024-0878.","DOI":"10.1515\/cclm-2024-0878"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_026","doi-asserted-by":"crossref","unstructured":"Neurauter, AA, Bonyhadi, M, Lien, E, N\u00f8kleby, L, Ruud, E, Camacho, S, et al.. Cell isolation and expansion using Dynabeads. Adv Biochem Eng Biotechnol 2007;106:41\u201373. https:\/\/doi.org\/10.1007\/10_2007_072.","DOI":"10.1007\/10_2007_072"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_027","doi-asserted-by":"crossref","unstructured":"Chang, ZM, Zhang, R, Yang, C, Shao, D, Tang, Y, Dong, WF, et al.. Cancer-leukocyte hybrid membrane-cloaked magnetic beads for the ultrasensitive isolation, purification, and non-destructive release of circulating tumor cells. Nanoscale 2020;12:19121\u20138. https:\/\/doi.org\/10.1039\/d0nr04097e.","DOI":"10.1039\/D0NR04097E"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_028","doi-asserted-by":"crossref","unstructured":"Ni, C, Chen, Y, Zhou, Y, Jiang, D, Ni, Z, Xiang, N. Inertia-magnetic microfluidics for rapid and high-purity separation of malignant tumor cells. Sensor Actuator B Chem 2023;397:134619. https:\/\/doi.org\/10.1016\/j.snb.2023.134619.","DOI":"10.1016\/j.snb.2023.134619"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_029","doi-asserted-by":"crossref","unstructured":"Jiang, X, Zhang, X, Guo, C, Ma, B, Liu, Z, Du, Y, et al.. Genetically engineered cell membrane-coated magnetic nanoparticles for high-performance isolation of circulating tumor cells. Adv Funct Mater 2024;34:2304426. https:\/\/doi.org\/10.1002\/adfm.202304426.","DOI":"10.1002\/adfm.202304426"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_030","doi-asserted-by":"crossref","unstructured":"Feng, C, Wang, J, Yang, X, Zang, X, Zhou, H, Zhang, E, et al.. Construction and characterization of KRAS immune lipid magnetic balls for colorectal cancer circulating tumor cells. Cancer Manag Res 2020;12:10067\u201375. https:\/\/doi.org\/10.2147\/cmar.s258565.","DOI":"10.2147\/CMAR.S258565"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_031","doi-asserted-by":"crossref","unstructured":"Yoo, CE, Park, J-M, Moon, H-S, Joung, J-G, Son, D-S, Jeon, H-J, et al.. Vertical magnetic separation of circulating tumor cells for somatic genomic-alteration analysis in lung cancer patients. Sci Rep 2016;6:37392. https:\/\/doi.org\/10.1038\/srep37392.","DOI":"10.1038\/srep37392"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_032","doi-asserted-by":"crossref","unstructured":"Kielhorn, E, Schofield, K, Rimm, DL. Use of magnetic enrichment for detection of carcinoma cells in fluid specimens. Cancer 2002;94:205\u201311. https:\/\/doi.org\/10.1002\/cncr.10193.","DOI":"10.1002\/cncr.10193"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_033","doi-asserted-by":"crossref","unstructured":"Saliba, A-E, Saias, L, Psychari, E, Minc, N, Simon, D, Bidard, F-C, et al.. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci USA 2010;107:14524\u20139. https:\/\/doi.org\/10.1073\/pnas.1001515107.","DOI":"10.1073\/pnas.1001515107"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_034","doi-asserted-by":"crossref","unstructured":"Melichar, B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clin Chem Lab Med 2013;51:99\u2013112. https:\/\/doi.org\/10.1515\/cclm-2012-0496.","DOI":"10.1515\/cclm-2012-0496"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_035","doi-asserted-by":"crossref","unstructured":"Melichar, B. Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. Clin Chem Lab Med 2023;61:906\u201320. https:\/\/doi.org\/10.1515\/cclm-2022-1108.","DOI":"10.1515\/cclm-2022-1108"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_036","doi-asserted-by":"crossref","unstructured":"Clive, AO, Kahan, BC, Hooper, CE, Bhatnagar, R, Morley, AJ, Zahan-Evans, N, et al.. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014;69:1098\u2013104. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205285.","DOI":"10.1136\/thoraxjnl-2014-205285"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_037","doi-asserted-by":"crossref","unstructured":"Peng, P, Yang, Y, Du, J, Zhai, K, Shi, HZ. Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis. Cancer Cell Int 2022;22:99. https:\/\/doi.org\/10.1186\/s12935-022-02518-w.","DOI":"10.1186\/s12935-022-02518-w"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_038","doi-asserted-by":"crossref","unstructured":"Thakur, S, Rathor, A, Jain, S, Nambirajan, A, Khurana, S, Malik, PS, et al.. Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer. J Am Soc Cytopathol 2024;13:291\u2013302. https:\/\/doi.org\/10.1016\/j.jasc.2024.03.006.","DOI":"10.1016\/j.jasc.2024.03.006"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_039","doi-asserted-by":"crossref","unstructured":"Guan, Y, Wang, ZJ, Wang, LQ, Hua, DF, Liu, J. Comparison of EGFR mutation rates in lung adenocarcinoma tissue and pleural effusion samples. Genet Mol Res 2016;15:1\u20137. https:\/\/doi.org\/10.4238\/gmr.15027001.","DOI":"10.4238\/gmr.15027001"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_040","doi-asserted-by":"crossref","unstructured":"Yu, J, Xu, H, Feng, T, Xie, T, Shi, T. Identification of potential biomarkers of EGFR mutation in pleural effusion of non-small cell lung cancer patients based on metabolomics. Clin Lab 2024;70. https:\/\/doi.org\/10.7754\/clin.lab.2023.231105.","DOI":"10.7754\/Clin.Lab.2023.231105"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_041","doi-asserted-by":"crossref","unstructured":"Sugita, Y, Muraoka, D, Demachi-Okamura, A, Komuro, H, Masago, K, Sasaki, E, et al.. Candidate tumor-specific CD8(+) T\u00a0cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis. OncoImmunology 2024;13:2371556. https:\/\/doi.org\/10.1080\/2162402x.2024.2371556.","DOI":"10.1080\/2162402X.2024.2371556"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_042","doi-asserted-by":"crossref","unstructured":"Melichar, B, Freedman, RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 2002;12:3\u201317. https:\/\/doi.org\/10.1046\/j.1525-1438.2002.01093.x.","DOI":"10.1046\/j.1525-1438.2002.01093.x"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_043","doi-asserted-by":"crossref","unstructured":"Melichar, B, Nash, MA, Lenzi, R, Platsoucas, CD, Freedman, RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000;119:19\u201327. https:\/\/doi.org\/10.1046\/j.1365-2249.2000.01105.x.","DOI":"10.1046\/j.1365-2249.2000.01105.x"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_044","doi-asserted-by":"crossref","unstructured":"Melichar, B, Lenzi, R, Rosenblum, M, Kudelka, AP, Kavanagh, JJ, Melicharova, K, et al.. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 2003;26:270\u20136. https:\/\/doi.org\/10.1097\/00002371-200305000-00010.","DOI":"10.1097\/00002371-200305000-00010"},{"key":"2025042506015785114_j_cclm-2025-0197_ref_045","unstructured":"Freedman, RS, Kudelka, AP, Kavanagh, JJ, Verschraegen, C, Edwards, CL, Nash, M, et al.. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 2000;6:2268\u201378."},{"key":"2025042506015785114_j_cclm-2025-0197_ref_046","unstructured":"Freedman, RS, Vadhan-Raj, S, Butts, C, Savary, C, Melichar, B, Verschraegen, C, et al.. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 2003;9:5228\u201337."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0197\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0197\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:04:59Z","timestamp":1745561099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/cclm-2025-0197\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,5,26]]}},"alternative-id":["10.1515\/cclm-2025-0197"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2025-0197","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}